Article

Massimo Radin, MD, PhD: Low Complement Levels in Early Pregnancy Predicts Disease Flare in SLE 

Author(s):

Massimo Radin, MD, PhD, discusses how low complement levels in the first trimester can predict disease flare in pregnant patients with systemic lupus erythematosus.

Rheumatology Network interviewed Massimo Radin, MD, PhD, to discuss his upcoming European Alliance of Associations for Rheumatology (EULAR) 2022 presentation, “Low Complement Levels in the First Trimester Predict Disease Flare in SLE Pregnancy: A Network Meta-Analysis on 532 Patients.” Radin is a researcher at the University of Torino (UNITO).

“For this study, the methodology was a little bit different because we wanted to include a large cohort of patients without performing a traditional systematic review, where if you had missing data, you lose those patients. We wanted to be more thorough in our data analysis,” Radin explained.

Investigators collected data on all perspective pregnancies in women with systemic lupus erythematosus (SLE) that were currently available in the literature. They then contacted the lead investigators of those studies to collaborate and obtain additional information on how complement evolved during pregnancy. Ultimately, 12 studies were included in the analysis, evaluating over 500 patients.

“We know that monitoring complement is important in [patients with SLE], but the fluctuation of complement during pregnancy makes it harder,” Radin stated. Therefore, it is critical that rheumatologists monitor these levels. Tracking complement levels of patients with SLE is important because, generally, an increase of complement levels can correlate with disease activity and subsequent flares.

“Of course, [while] this is true for a lot of patients, for some [patients with SLE], this isn't true. This might be because some of the patients that we see have stronger genetic factors that are associated with complement that are the directly responsible for their SLE pathogenesis,” Radin noted.

Related Videos
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
© 2024 MJH Life Sciences

All rights reserved.